Therapy of metastatic malignant melanoma: on the way to individualized disease control

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Metastatic malignant melanoma has historically presented therapeutic challenges.
• Identification of molecular drivers has enabled targeted therapy development.

Purpose of the Study:

• To review advancements in targeted therapies for metastatic melanoma.
• To discuss strategies for overcoming therapeutic resistance and improving patient outcomes.

Main Methods:

• Review of B-RAF inhibitors targeting the MAP kinase cascade.
• Discussion of immunomodulating antibodies (anti-CTLA4, anti-PD1).
• Exploration of cancer stem cell targeting strategies.

Main Results:

• B-RAF inhibitors achieve objective responses in ~50% of BRAF-mutated melanoma, but remissions are often short-lived (5-6 months).
• Combination therapies and immunotherapies show promise for sustained disease control.
• Cancer stem cells are implicated in primary drug resistance and acquired resistance.

Conclusions:

• Targeted therapies have improved melanoma treatment, but resistance remains a significant hurdle.
• Combining targeted agents with immunotherapy and addressing cancer stem cells are key future directions.
• Individualized treatment strategies are crucial for achieving long-term control and potential cure of metastatic melanoma.